A hallmark of the successful clinical development of targeted therapies is the identification of the patient subgroups most likely to benefit from these agents. Recent clinical studies evaluating molecules targeting the MET signaling pathway, including onartuzumab and rilotumumab, have demonstrated benefit in patients whose tumors express high levels of MET protein. We describe the development, performance, and scoring criteria of a MET IHC test that differentiated patient outcomes for onartuzumab plus erlotinib versus erlotinib alone in a recent Phase II study in NSCLC. In a retrospective analysis of this study, multiple biomarkers related to MET and/or EGFR signaling were additionally examined. It was determined that the IHC test to detect tumor MET levels represented the best predictor of benefit. These results have guided the Conclusions: MET IHC remains the most robust predictor of OS and PFS benefit from O+E relative to all examined exploratory markers.
Statement of Translational Relevance
A hallmark of the successful clinical development of targeted therapies is the identification of the patient subgroups most likely to benefit from these agents. Recent clinical studies evaluating molecules targeting the MET signaling pathway, including onartuzumab and rilotumumab, have demonstrated benefit in patients whose tumors express high levels of MET protein. We describe the development, performance, and scoring criteria of a MET IHC test that differentiated patient outcomes for onartuzumab plus erlotinib versus erlotinib alone in a recent Phase II study in NSCLC. In a retrospective analysis of this study, multiple biomarkers related to MET and/or EGFR signaling were additionally examined. It was determined that the IHC test to detect tumor MET levels represented the best predictor of benefit. These results have guided the Phase III clinical development strategy for onartuzumab and provided further support for development of the MET IHC test as a potential companion diagnostic.
Introduction
MET, a receptor tyrosine kinase that binds hepatocyte growth factor (HGF) is frequently overexpressed in a variety of human malignancies. MET activation has been implicated in tumorigenesis, and MET signaling can be dysregulated through a variety of genetic or epigenetic mechanisms in cancer (1, 2) . In non-small cell lung cancer (NSCLC), tumor MET receptor protein expression, HGF protein expression, and high MET gene copy number are indicative of poor prognosis (3) (4) (5) (6) . Although focal amplification of the MET gene is rare in primary lung tumors (~1% to 7%) (4) , it is associated with oncogenic addiction, and with sensitivity, in preclinical models, to small molecule inhibitors (SMIs) targeting MET (7, 8) . No activating mutations have been identified in the kinase domain of MET in NSCLC; however, somatic variants causing exon 14 skipping, can result in an alternatively spliced MET receptor lacking the juxtamembrane domain that sustains enhanced ligand-dependent MET signaling (9) .
Finally, genetic polymorphisms have been linked to enhanced MET signaling (R970C, T990I) (10) , as well as to lower HGF binding affinity (N375S) (11) .
A growing body of evidence has emerged to support a link between the MET and epidermal growth factor receptor (EGFR) signaling pathways. These receptor tyrosine kinases are often co-expressed in tumors, and evidence exists for functional transactivation that may amplify downstream signals (12) . For example, activation of EGFR may occur through MET amplification or HGF-mediated induction of EGFR ligands (13) . MET activation has been associated with resistance to EGFR inhibitors both preclinically and clinically (14) (15) (16) . Collectively, these findings support the rationale for dual inhibition of MET and EGFR signaling. Author Manuscript Published OnlineFirst on March 31, 2014; DOI: 10.1158/1078-0432.CCR- Onartuzumab (MetMAb) is a recombinant, humanized, monovalent monoclonal antibody targeting MET (17) . A Phase II study (OAM4558g) evaluated onartuzumab plus erlotinib (O+E) versus placebo plus erlotinib (p+E) in patients with second-/third-line NSCLC therapy (18) . Patient tumor samples were evaluated for MET expression by immunohistochemistry (IHC) and were classified as MET-positive or MET-negative, after randomization, but prior to unblinding the treatment assignment. There was neither a progression-free survival (PFS) (HR 1.09; P = 0.69), nor overall survival (OS) benefit (HR 0.80; P = 0.34), in the intent-to-treat (ITT) population. However, the combination of O+E in MET-positive disease resulted in improved PFS and OS (HR 0.53, P = 0.04; HR 0.37, P = 0.002, respectively) (18) .
In this article we describe the development and validation of the specific IHC assay and the corresponding scoring system that was used to assess MET protein expression in the OAM4558g clinical trial. In addition, we carry out retrospective analyses to further assess the diagnostic cut-point and evaluate additional biomarkers related to the MET and/or EGFR pathways, as predictors of benefit from onartuzumab plus erlotinib.
Materials and Methods

Patients
Patients aged ≥18 years with measurable and previously treated (up to two prior regimens) stage IIIB/IV NSCLC were eligible. Submission of tumor tissue (archival permitted), as either a tissue block or unstained serial slides, was required. Written informed consent was obtained prior to any study-specific screening procedures. A total of 137 patients were randomized; 68 to p+E and 69 to O+E. Demographic and baseline characteristics were generally well balanced across the treatment arms in the ITT and MET diagnostic subgroups, with few exceptions noted. A similar pattern in these characteristics was also observed across the treatment arms in the subgroups of FISH evaluable patients and quantitative reverse transcription polymerase chain reaction (qRT-PCR) evaluable patients (data not shown). Prioritization of specific biomarker analyses and number of tissues examined for the given analysis was as follows: MET IHC (n = 128), EGFR/KRAS mutation analysis (n = 112), MET/EGFR FISH (n = 96), MET exon14 (n = 87) and N375S genotyping (n = 113) and finally, qRT-PCR (n = 67).
Plasma HGF levels were evaluated from 96 patients. The overlap in biomarker analyses is shown in Supplementary Table S1 .
Study design
This was a Phase II double-blinded, multicenter, international randomized clinical trial (OAM4558g). Patients were randomly assigned in a 1:1 ratio to receive either onartuzumab (15 mg/kg) or placebo (both administered by intravenous infusion every 3 weeks), plus erlotinib (oral 150 mg daily). The co-primary endpoints were PFS in the ITT and MET-positive populations. Approximately 120 patients would be needed to estimate the PFS benefit in both these populations. Further details of the study design have been published previously (18) .
MET expression by IHC
MET expression levels were evaluated using CONFIRM anti-total MET (SP44) rabbit monoclonal primary antibody (Ventana Medical Systems, Inc.; cat no. 790-4430), and a composite scoring system was devised to determine the status of MET. The IHC cutpoint for positivity was prospectively defined in OAM4558g. The scoring of OAM4558g specimens was independently reviewed by a second pathologist, with an 88.3% concordance in calling MET-positive between pathologists. We did not observe a sc-8432; Santa Cruz Biotechnology, Santa Cruz, California). A polyclonal antibody raised against MST1R was a kind gift from Dr Amitabha Chaudhuri (Genentech, Inc.).
Molecular assessments
MET and EGFR gene copy numbers were evaluated by FISH; a CEP7 centromere probe (Abbott Molecular) was used as a control. High-level MET amplification was defined as tight gene clusters of ≥15 copies in ≥10% of tumor cells, or a MET:CEP7 ratio of ≥2. A cut-off of ≥5 copies of MET/cell was predefined as the criterion for FISH-positive status (FISH+), based on prior prognostic data supporting this cut-off in NSCLC (4).
Tumors were considered EGFR FISH+ based on a scoring system utilized in multiple clinical studies (19) 
HGF quantification by ELISA
Plasma HGF levels were measured by ELISA, as described previously (20) .
Statistical analysis
PFS was defined as the time from randomization to the first occurrence of disease progression or death on study from any cause, or to the last tumor assessment date if patients were progression free. OS was determined from randomization to the date of death, or the last known patient contact. For each treatment arm, the median PFS and OS were estimated from Kaplan-Meier curves.
The PFS and OS treatment comparisons were based on a log-rank test at the 0.05 level of significance (2-sided 
Results
Development of the SP44 IHC test
To identify antibodies that would be suitable for detecting MET protein expression levels in formalin-fixed paraffin-embedded tissue specimens, we initially which 5D5 did not bind ( Supplementary Fig. S2B and S2C ). Finally, a statistically significant association was observed between the intensity of IHC staining with SP44
and MET mRNA levels across a larger panel of NSCLC cell lines ( Supplementary   Fig. S3 ) further supporting the specificity of this reagent.
In NSCLC tissues, heterogeneity in the intensity was frequently observed within individual NSCLC tumors ( Supplementary Fig. S4 ). To account for this heterogeneity, a comprehensive clinical scoring system was developed that evaluated both membranous and cytoplasmic staining intensity and percent of cells staining at a given intensity level (Supplementary Table S3 ). A proportional cut-off of ≥50% was selected to ensure that a majority of the cells within a given specimen expressed MET at either a weak (clinical score = 1+), moderate (clinical score = 2+), or strong (clinical score = 3+) intensity level.
Specimens with no or equivocal staining in tumor cells or <50% of tumor cells staining at any given intensity were considered negative (clinical score = 0). Using these IHC scoring criteria we continued to observe a statistically significant (Jonckheere-Terpstra P < 0.0001) relationship with MET mRNA expression in tumor specimens ( Table S4 ). Although variation was observed in the proportion of cells staining at a given intensity, there was complete concordance in the final IHC score for the multiple tissue specimens in these patients. Finally, using these scoring criteria, we determined that 58% (±6%) of non-squamous and 26% (±11%) of squamous cell tumor specimens were MET-positive across three separate series of NSCLC tumor specimens (Table 1) . 
Evaluation of alternative scoring systems
We also evaluated the H-score method of semi-quantitatively assessing MET expression as an alternative to take into account the intensity and heterogeneity of MET staining (21) . Both membranous and cytoplasmic staining were combined into a single intensity score. We observed a range of H-scores from 0 to 300, with a median H-score of 160 in the set of tissue samples collected from patients in OAM4558g. Most specimens within each clinical score category (0, 1+, 2+, and 3+) were distributed around the H-scores of 0, 100, 200, and 300, respectively (Supplementary Figs. S5 and S6), as would be expected if staining was completely homogeneous. When heterogeneity in staining intensity was present (n = 64 specimens exhibiting tumor cell populations with multiple staining intensity levels), positivity was primarily distributed between two different staining intensity levels (n = 48). Only 13% of specimens (n = 16) exhibited a significant degree of heterogeneity in which staining intensities were noted across 3 different levels.
There were four specimens below the median H-score that were considered METpositive when applying the clinical scoring algorithm; conversely, there was one specimen at the median H-score that was MET-negative by the clinical scoring system.
Defining the best cut-off for the MET IHC assay
The IHC cut-point for positivity was prospectively defined in OAM4558g. An analysis evaluating the appropriateness of this cut-point revealed that alternative proportional cut-points to define MET-positivity of ≥10% or ≥90% of tumor cells staining moderately or strongly did not result in a better differentiation of patient outcomes (18) .
To evaluate alternative cut-points in more detail, we examined PFS ( Fig. 2A) and OS (Fig. 2B ) based upon individual staining intensities using a 10%, 50%, or 90%
proportional cut-off. Consistent with prior results, the best differentiation of patient outcomes was observed at the 50% cut-off and the differentiation was not greatly altered by applying different cut-offs to different staining intensities. More importantly, PFS was also analyzed in two subsets of patients whose IHC scores bordered the diagnostic cutoff: (1) group 1: patients categorized as MET-positive using a 10% cut-off but as METnegative using 50% cut-off (patients whose tumors exhibited moderate to strong staining in 10-49% of tumor cells , Fig. 2C) ; and (2) group 2: patients categorized as MET-positive using 50% cut-off, but as MET-negative using a 90% cut-off (patients whose tumors exhibited moderate to strong staining in 50-89% of tumor cells, Fig. 2D ). In group 1 (n = 21), patients treated with O+E had shorter PFS than patients treated with p+E (HR 3.065; P = 0.04), suggesting that using a 10% cut-off may incorporate patients who may not benefit from the study drug. Outcomes in group 2 patients were not statistically different between treatment arms, however there was a trend toward benefit in those who received O+E (n = 19; HR 0.47; P = 0.23). Similar findings were observed for OS (data not shown).
Evaluation of alternative predictive markers of onartuzumab + erlotinib activity
Pathway mutations
EGFR and KRAS genotyping data were obtained from 112 patients, mutations were identified in 13 (12%) and 26 (23%) samples, respectively, and were mutually exclusive. in MET N375S were found in 12 of 113 (11%) tumors tested; due to an imbalance between treatment subgroups, no further analysis was carried out. (Fig. 3C ). An OS HR of 0.51 (P = 0.13) and a PFS HR of 0.44 (P = 0.10) was observed in the MET IHC+/FISH-and EGFR wt patients (Fig. 3D ).
MET/EGFR copy number
Due to chromosome 7 polyploidy, gains in MET gene copy number have been shown to associate with high EGFR copy number gains (4). To ensure an unbiased analysis, EGFR and MET copy number variations were evaluated using identical criteria, as previously adopted for use in EGFR FISH testing (19) . A significant association between EGFR and MET copy number was observed (Fisher exact, P = 2.2×10 ( Supplementary Fig. S9 ). No correlation of plasma HGF with tumor HGF mRNA levels was observed (data not shown). In this subpopulation of patients with evaluable plasma HGF data, both OS and PFS were consistent with what was observed in the general population: HR 0.39 (P = 0.006) in OS and HR 0.52 (P = 0.06) in PFS, respectively, in MET-positive patients. In patients who had baseline HGF protein below the median, the OS HR was 0.52 (P = 0.09) and PFS HR was 0.56 (P = 0.10) favoring O+E (Fig. 5A ). In patients with baseline HGF protein ≥median, the OS HR was 1.23 (P = 0.56) (Fig. 5B) . In addition, a Cox proportional hazard regression model revealed no statistically significant association between OS and HGF level (HR 0.81; 95% CI, 0.52-1.25; P = 0.339) or between OS and HGF level and treatment (HR 1.68; 95% CI, 0.91-3.10; P = 0.096).
Discussion
In the OAM4558g study, the addition of onartuzumab to erlotinib resulted in improvements in both PFS and OS in patients whose tumor specimens were determined to be MET-positive by IHC (18) . This benefit was not seen in the overall population, and patients with MET-negative tumors who received O+E had a worse outcome versus those treated with erlotinib alone. Therefore, the data indicate that the MET IHC assay may be a reliable diagnostic test for identifying NSCLC patients most likely to benefit from O+E; and as such, this test is currently being developed as a companion diagnostic for onartuzumab in combination with erlotinib (clinicaltrials.gov identifier: NCT01456325) (22) . In this report, we describe the development and performance of this IHC test and compare its performance relative to alternative biomarkers.
Our investigation has identified that the SP44 monoclonal antibody binds MET with high specificity and generates a range of staining intensities that correlate well with MET mRNA levels and MET protein levels determined by alternative means. As with many histologic tests, we observed intratumoral heterogeneity in MET protein expression levels in NSCLC tissues. To account for such heterogeneity, we examined various scoring systems that incorporate both staining intensity and percent malignant cell positivity. We reasoned that a cut-off that captures the MET expression signal in the majority of the malignant cell population in a specimen (i.e., ≥50%) would likely produce more reproducible findings. When using a cut-off of 50% of malignant cells in a biopsy sample with moderate and/or strong staining intensity, we observed that our call for positivity did not change when evaluating intratumoral heterogeneity in a small set of cases for which sections representing more than one area of the same resection specimen were available for analysis (Supplementary Table S4 ). More importantly, we demonstrated that this 50% cut-off was the criterion that best differentiated patient outcomes in the Phase II OAM4558g trial. A less stringent cut-off of 10% of malignant cells staining at moderate and/or strong intensity resulted in the inclusion of a subset of patients who did not benefit from O+E therapy in this trial, as shown by worse outcomes (PFS HR 3.065; P = 0.04).
Conversely, implementation of a more stringent cut-off of 90% of malignant cells staining at moderate and/or strong intensity would result in the loss of a subset of patients who trended toward improved outcomes with O+E, although this did not achieve statistical significance (PFS HR 0.464; P = 0.23). Additional evaluations of outcome based on different staining intensities supported these proposed criteria.
Overall, these data strongly suggest that the diagnostic cut-off that was prospectively defined represents a suitable scoring system for future clinical studies evaluating O+E in NSCLC. Other scoring criteria, such as H-score, were considered. However, exploratory analysis did not show that H-score could alter the interpretation of the outcomes from previous analyses (data not shown). 
KRAS is a downstream effector of both EGFR and MET signaling and mutations
in this gene provide a critical predictive marker for efficacy of EGFR-targeted antibodies in colorectal cancer. Although KRAS mutations predict for a lack of radiologic response to EGFR-targeted SMIs in NSCLC, any similar impact on PFS and OS remains unresolved (23, 24) . In this study, the incidence of KRAS mutations was mutually exclusive from EGFR mutations, and did not significantly impact outcomes in patients receiving O+E in the ITT, MET-positive or MET-negative populations. However, given limitation in sample size, it remains to be determined whether this subgroup would indeed benefit from a MET inhibitor. The role of high-level MET gene amplification has gained considerable attention, as it predicts for enhanced sensitivity to MET-targeted SMIs in preclinical models (7, 8) , has recently been linked to anecdotal responses on MET-targeted agents in the clinic (25) , and importantly, represents a mechanism of acquired 
Tumor mRNA expression of key MET and EGFR pathway genes was additionally evaluated as alternative predictive biomarkers. This not only included expression of MET/HGF, but expression levels of two EGFR ligands that can be transcriptionally regulated by MET activation, AREG and EREG. MET was the only mRNA biomarker examined that showed a trend toward improvement in OS and PFS, albeit this did not achieve statistical significance. This could likely be attributed to the small sample size, as only ~1/2 of the patients (n = 67) had material remaining following the prioritization of other biomarker assessments for transcriptional analysis. Regardless, evaluation of MET mRNA levels as an alternative predictive biomarker may warrant further investigation in future studies.
High serum or plasma HGF levels have been associated with poor prognosis in several cancers, including NSCLC (26) (27) (28) . In a study of patients with NSCLC treated with EGFR SMIs, high serum HGF was associated with worse outcome (tumor response, PFS, and OS) (26) . Despite our expectations that the addition of onartuzumab to erlotinib could improve outcomes versus erlotinib alone in patients with high plasma HGF at baseline, we did not observe a statistically significant association. In fact, a non-significant trend toward benefit was observed in patients with low baseline HGF. The study cited from Kasahara et al., evaluated serum HGF, whereas our study evaluated plasma HGF. However, this would unlikely explain the difference, as strong correlations between plasma and serum HGF levels have been observed (data not shown). High plasma HGF also failed to show a prognostic link in the p+E arm in our study (OS HR 0.75; P = 0.41), suggesting that the prognostic significance of circulating HGF may be influenced by differences in the population tested. It remains to be elucidated how HGF levels in circulation relate to intratumoral levels of HGF. Although elevated circulating HGF levels have been observed in subsets of cancer patients, elevated circulating HGF levels have additionally been described in other settings, including certain viral or bacterial infections, graft versus host disease and surgical procedures (29-31).
In conclusion, MET IHC was a reliable and accurate assay for identifying NSCLC patients most likely to benefit from O+E, and outperformed the other examined exploratory markers. The retrospective, exploratory nature of these analyses, combined with small sample size, limit the scope of definitive conclusions to be drawn from these alternative biomarkers. Further investigations of these biomarkers using larger sample sizes are necessary to determine whether any would be useful in conjunction with MET IHC to better define subpopulations most likely to benefit from onartuzumab plus erlotinib. In addition, it will be imperative to determine whether such biomarkers will be useful in determining benefit to other onartuzumab- proportional cut-offs (10%, 50%, and 90%). Kaplan-Meier estimates for progression-free survival in patients with IHC scores bordering the diagnostic cut-off: (C) patients defined as MET-positive using a 10% cut-off and MET-negative using a 50% cut-off; (D) patients defined as MET-positive using a 50% cut-off and MET-negative using a 90% cut-off. clincancerres.aa Downloaded from Baseline risk factor Research.
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